ProCE Banner Activity

Perspectiva global sobre los datos de tratamientos emergentes con inhibidores de TQB para LLC y LCM en recidiva/refractarios en 2022

Text Module
Lea las opiniones y comentarios expertos sobre los datos de mayor relevancia clínica de la leucemia linfocítica crónica y el linfoma de células del manto presentados en las Juntas Anuales de ASCO, EHA, la Conferencia Pan-Pacífico sobre Linfomas, ESMO y SOHO de 2022.

Released: January 23, 2023

Expiration: January 22, 2024

No longer available for credit.

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Matthew S. Davids

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Toby Eyre

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Brad S. Kahl

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Kami Maddocks

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor: AbbVie, Gilead Sciences, Janssen-Cilag, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc:consultant: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, Ono Pharmaceuticals, Research to Practice, Takeda, TG Therapeutics, Verastem, Zentalis; researcher: AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem.

Toby Eyre, MBChB, MD

Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Toby Eyre, MBChB, MD: advisor: AbbVie, AstraZeneca, Incyte, Janssen, Kite/Gilead, Lilly, Loxo, Roche.

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS: consultant/advisor/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol-Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; researcher (paid to institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Brad S. Kahl, MD:consultant: AbbVie, Acerta Pharma, ADCT Therapeutics, AstraZeneca, Celgene, Genentech, MEI, Morphosys, Pharmacyclics, Roche, TG Therapeutics.

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, Acerta, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Genmab, Gilead, Incyte, Janssen, Kite, Lilly, Morphosys, Pharmacyclics.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE:consultant: AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; researcher: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA:consultant/advisor: AbbVie, AstraZeneca, Caribou, Daiichi Sankyo, Genentech, Lilly, MEI Pharma, MorphoSys, Pharmacyclics.